147 related articles for article (PubMed ID: 3489080)
1. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease.
Atkins MB; Gould JA; Allegretta M; Li JJ; Dempsey RA; Rudders RA; Parkinson DR; Reichlin S; Mier JW
J Clin Oncol; 1986 Sep; 4(9):1380-91. PubMed ID: 3489080
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
3. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
Creekmore SP; Harris JE; Ellis TM; Braun DP; Cohen II; Bhoopalam N; Jassak PF; Cahill MA; Canzoneri CL; Fisher RI
J Clin Oncol; 1989 Feb; 7(2):276-84. PubMed ID: 2783732
[TBL] [Abstract][Full Text] [Related]
5. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
[TBL] [Abstract][Full Text] [Related]
9. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
Kolitz JE; Welte K; Wong GY; Holloway K; Merluzzi VJ; Engert A; Bradley EC; Konrad M; Polivka A; Gabrilove JL
J Biol Response Mod; 1987 Aug; 6(4):412-29. PubMed ID: 3498011
[TBL] [Abstract][Full Text] [Related]
10. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Levitt D; Fefer A
J Clin Oncol; 1988 Apr; 6(4):669-78. PubMed ID: 3258631
[TBL] [Abstract][Full Text] [Related]
11. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
Lotze MT; Frana LW; Sharrow SO; Robb RJ; Rosenberg SA
J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
[TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
13. [A phase I study of recombinant interleukin 2 (S6820)].
Takaku F
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3271-6. PubMed ID: 3058043
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.
Atkins MB; Vachino G; Tilg HJ; Karp DD; Robert NJ; Kappler K; Mier JW
J Clin Oncol; 1992 Nov; 10(11):1802-9. PubMed ID: 1403061
[TBL] [Abstract][Full Text] [Related]
15. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
Lotze MT; Matory YL; Ettinghausen SE; Rayner AA; Sharrow SO; Seipp CA; Custer MC; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2865-75. PubMed ID: 2993418
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung.
Ziegler LD; Palazzolo P; Cunningham J; Janus M; Itoh K; Hayakawa K; Hellstrom I; Hellstrom KE; Nicaise C; Dennin R
J Clin Oncol; 1992 Sep; 10(9):1470-8. PubMed ID: 1517790
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM
Ann Oncol; 1994 May; 5(5):447-52. PubMed ID: 7521206
[TBL] [Abstract][Full Text] [Related]
18. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
20. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
Atzpodien J; Körfer A; Evers P; Franks CR; Knüver-Hopf J; Lopez-Hänninen E; Fischer M; Mohr H; Dallmann I; Hadam M
Mol Biother; 1990 Mar; 2(1):18-26. PubMed ID: 2334534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
